AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease

Extract Antimicrobial therapies, such as antibiotics and antifungals, occupy an important place in the treatment of patients with chronic respiratory diseases, such as bronchiectasis (including related to underlying cystic fibrosis (CF) and primary ciliary dyskinesia (PCD)) and COPD. These patients often become colonised with respiratory pathogens, which may cause chronic infection and play a role in acute exacerbations, episodes of increased airway inflammation with respiratory symptoms, that are usually infectious in origin. Depending on the underlying disease and patient conditions, antibiotics are commonly used to eradicate colonising pathogens, suppress pathogens in chronic infection, treat acute exacerbations or widely as prophylaxis (e.g. macrolides) across chronic lung disease, including asthma and COPD [1–3].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research